Treating the Metabolic Syndrome by Fecal Transplantation—Current Status
The intestinal microbiome (IM) is important for normal gastrointestinal (GI) and other organ systems’ functioning. An alteration in the normal IM, dysbiosis, and changes in intestinal motility result in microorganisms’ overgrowth and an alteration in intestinal permeability. The gut–brain axis is al...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-05-01
|
| Series: | Biology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-7737/10/5/447 |
| _version_ | 1797533442734292992 |
|---|---|
| author | Stephen D. H. Malnick David Fisher Marina Somin Manuela G. Neuman |
| author_facet | Stephen D. H. Malnick David Fisher Marina Somin Manuela G. Neuman |
| author_sort | Stephen D. H. Malnick |
| collection | DOAJ |
| description | The intestinal microbiome (IM) is important for normal gastrointestinal (GI) and other organ systems’ functioning. An alteration in the normal IM, dysbiosis, and changes in intestinal motility result in microorganisms’ overgrowth and an alteration in intestinal permeability. The gut–brain axis is also of importance in the irritable bowel syndrome (IBS) and associated bowel overgrowth. Secondary to the epidemic of obesity, the metabolic syndrome has become a major health problem. Disturbances in the fecal microbiome are associated with the metabolic syndrome. Metabolic-associated fatty liver disease (MAFLD) is now the current terminology for non-alcoholic fatty liver disease. IM alteration by fecal transplantation is an approved treatment method for recurrent <i>Clostridioides difficile</i> infection. Initially performed by either duodenal infusion or colonoscopy, it is now easily performed by the administration of capsules containing stools. We discuss the intestinal microbiome—its composition, as well as the qualitative changes of microbiome composition leading to inflammation. In addition, we discuss the evidence of the effect of fecal transplantation on the metabolic syndrome and MAFLD, as well as its clinical indications. |
| first_indexed | 2024-03-10T11:14:36Z |
| format | Article |
| id | doaj.art-d48f8ac97cfb4f86a0610e0fbcda8bc8 |
| institution | Directory Open Access Journal |
| issn | 2079-7737 |
| language | English |
| last_indexed | 2024-03-10T11:14:36Z |
| publishDate | 2021-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biology |
| spelling | doaj.art-d48f8ac97cfb4f86a0610e0fbcda8bc82023-11-21T20:31:54ZengMDPI AGBiology2079-77372021-05-0110544710.3390/biology10050447Treating the Metabolic Syndrome by Fecal Transplantation—Current StatusStephen D. H. Malnick0David Fisher1Marina Somin2Manuela G. Neuman3Department of Internal Medicine Cj Kaplan Medical Center, The Hebrew University, Rehovot 76100, IsraelDepartment of Internal Medicine Cj Kaplan Medical Center, The Hebrew University, Rehovot 76100, IsraelDepartment of Internal Medicine Cj Kaplan Medical Center, The Hebrew University, Rehovot 76100, IsraelIn Vitro Drug Safety and Biotechnology, Banting Institute, University of Toronto, Toronto, ON M5G 0A3, CanadaThe intestinal microbiome (IM) is important for normal gastrointestinal (GI) and other organ systems’ functioning. An alteration in the normal IM, dysbiosis, and changes in intestinal motility result in microorganisms’ overgrowth and an alteration in intestinal permeability. The gut–brain axis is also of importance in the irritable bowel syndrome (IBS) and associated bowel overgrowth. Secondary to the epidemic of obesity, the metabolic syndrome has become a major health problem. Disturbances in the fecal microbiome are associated with the metabolic syndrome. Metabolic-associated fatty liver disease (MAFLD) is now the current terminology for non-alcoholic fatty liver disease. IM alteration by fecal transplantation is an approved treatment method for recurrent <i>Clostridioides difficile</i> infection. Initially performed by either duodenal infusion or colonoscopy, it is now easily performed by the administration of capsules containing stools. We discuss the intestinal microbiome—its composition, as well as the qualitative changes of microbiome composition leading to inflammation. In addition, we discuss the evidence of the effect of fecal transplantation on the metabolic syndrome and MAFLD, as well as its clinical indications.https://www.mdpi.com/2079-7737/10/5/447fecal transplantationinflammatory mediatorsmetabolic syndromemicrobiomemetabolic-associated fatty liver diseasenon-alcoholic fatty liver disease |
| spellingShingle | Stephen D. H. Malnick David Fisher Marina Somin Manuela G. Neuman Treating the Metabolic Syndrome by Fecal Transplantation—Current Status Biology fecal transplantation inflammatory mediators metabolic syndrome microbiome metabolic-associated fatty liver disease non-alcoholic fatty liver disease |
| title | Treating the Metabolic Syndrome by Fecal Transplantation—Current Status |
| title_full | Treating the Metabolic Syndrome by Fecal Transplantation—Current Status |
| title_fullStr | Treating the Metabolic Syndrome by Fecal Transplantation—Current Status |
| title_full_unstemmed | Treating the Metabolic Syndrome by Fecal Transplantation—Current Status |
| title_short | Treating the Metabolic Syndrome by Fecal Transplantation—Current Status |
| title_sort | treating the metabolic syndrome by fecal transplantation current status |
| topic | fecal transplantation inflammatory mediators metabolic syndrome microbiome metabolic-associated fatty liver disease non-alcoholic fatty liver disease |
| url | https://www.mdpi.com/2079-7737/10/5/447 |
| work_keys_str_mv | AT stephendhmalnick treatingthemetabolicsyndromebyfecaltransplantationcurrentstatus AT davidfisher treatingthemetabolicsyndromebyfecaltransplantationcurrentstatus AT marinasomin treatingthemetabolicsyndromebyfecaltransplantationcurrentstatus AT manuelagneuman treatingthemetabolicsyndromebyfecaltransplantationcurrentstatus |